|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Roy I, Evans DB and Dwinell MB: Chemokines
and chemokine receptors: Update on utility and challenges for the
clinician. Surgery. 155:961–973. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chatterjee S, Azad Behnam B and Nimmagadda
S: The intricate role of CXCR4 in cancer. Adv Cancer Res.
124:31–82. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Muller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W and Wagner SN:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sarvaiya PJ, Guo D, Ulasov I, Gabikian P
and Lesniak MS: Chemokines in tumor progression and metastasis.
Oncotarget. 4:2171–2185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Y, Zhang C, Xu W, Zhang J, Zheng Y, Lu
Z, Liu D and Jiang K: CXC motif chemokine receptor 4 gene
polymorphism and cancer risk. Medicine (Baltimore). 95:e53172016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao H, Guo L, Zhao H, Zhao J, Weng H and
Zhao B: CXCR4 over-expression and survival in cancer: A system
review and meta-analysis. Oncotarget. 6:5022–5040. 2015.PubMed/NCBI
|
|
9
|
Zhou XM, He L, Hou G, Jiang B, Wang YH and
Zhao L: Clinicopathological significance of CXCR4 in non-small cell
lung cancer. Drug Des Devel Ther. 9:1349–1358. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang L, Wang Z, Liu X and Liu F:
High-level C-X-C chemokine receptor type 4 expression correlates
with brain-specific metastasis following complete resection of
non-small cell lung cancer. Oncol Lett. 7:1871–1876. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wald O, Shapira OM and Izhar U:
CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic
roles and therapeutic potential. Theranostics. 3:26–33. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu T, Li X, You S, Bhuyan SS and Dong L:
Effectiveness of AMD3100 in treatment of leukemia and solid tumors:
From original discovery to use in current clinical practice. Exp
Hematol Oncol. 5:192016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brennecke P, Arlt MJ, Campanile C, Husmann
K, Gvozdenovic A, Apuzzo T, Thelen M, Born W and Fuchs B: CXCR4
antibody treatment suppresses metastatic spread to the lung of
intratibial human osteosarcoma xenografts in mice. Clin Exp
Metastasis. 31:339–349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ullman-Cullere MH and Foltz CJ: Body
conditioning scoring: A rapid and accurate method for assessing
health status in mice. Lab Anim Sci. 49:319–323. 1999.PubMed/NCBI
|
|
15
|
Sun X, Charbonneau C, Wei L, Yang W, Chen
Q and Terek RM: CXCR4-targeted therapy inhibits VEGF expression and
chondrosarcoma angiogenesis and metastasis. Mol Cancer Ther.
12:1163–1170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marechal R, Demetter P, Nagy N, Berton A,
Decaestecker C, Polus M, Closset J, Devière J, Salmon I and Van
Laethem JL: High expression of CXCR4 may predict poor survival in
resected pancreatic adenocarcinoma. Br J cancer 5. 100:1444–1451.
2009. View Article : Google Scholar
|
|
17
|
Sood AK, Fletcher MS, Gruman LM, Coffin
JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA and Hendrix
MJ: The paradoxical expression of maspin in ovarian carcinoma. Clin
Cancer Res. 8:2924–2932. 2002.PubMed/NCBI
|
|
18
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis-correlation in invasive breast
carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y, Wu BQ, Geng H, Xu ML and Zhong HH:
Association of chemokine and chemokine receptor expression with the
invasion and metastasis of lung carcinoma. Oncol Lett.
10:1315–1322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gil M, Seshadri M, Komorowski MP, Abrams
SI and Kozbor D: Targeting CXCL12/CXCR4 signaling with oncolytic
virotherapy disrupts tumor vasculature and inhibits breast cancer
metastases. Proc Natl Acad Sci USA. 110:E1291–E1300. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Choi WT, Yang Y, Xu Y and An J: Targeting
chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor
progression, and metastasis. Curr Top Med Chem. 14:1574–1589. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang S, Peng X, Li X, Yang P, Xie L, Li
Y, Du C and Zhang G: Silencing of CXCR4 sensitizes triple-negative
breast cancer cells to cisplatin. Oncotarget. 6:1020–1030. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
DiPersio JF, Stadtmauer EA, Nademanee A,
Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf
S, Horwitz M, et al: Plerixafor and G-CSF versus placebo and G-CSF
to mobilize hematopoietic stem cells for autologous stem cell
transplantation in patients with multiple myeloma. Blood.
113:5720–5726. 2009.PubMed/NCBI
|
|
24
|
Nikkhoo B, Jalili A, Fakhari S,
Sheikhesmaili F, Fathi F, Rooshani D, Feizi Hoseinpour MA and
Nikzaban M: Nuclear pattern of CXCR4 expression is associated with
a better overall survival in patients with gastric cancer. J Oncol.
2014:8080122014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Spano JP, Andre F, Morat L, Sabatier L,
Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, et
al: Chemokine receptor CXCR4 and early-stage non-small cell lung
cancer: Pattern of expression and correlation with outcome. Ann
Oncol. 15:613–617. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Popple A, Durrant LG, Spendlove I, Rolland
P, Scott IV, Deen S and Ramage JM: The chemokine, CXCL12, is an
independent predictor of poor survival in ovarian cancer. Br J
Cancer. 106:1306–1313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Minamiya Y, Saito H, Takahashi N, Ito M,
Imai K, Ono T, Motoyama S and Ogawa J: Expression of the chemokine
receptor CXCR4 correlates with a favorable prognosis in patients
with adenocarcinoma of the lung. Lung Cancer. 68:466–471. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yadav SS, Prasad SB, Das M, Kumari S,
Pandey LK, Singh S, Pradhan S and Narayan G: Epigenetic silencing
of CXCR4 promotes loss of cell adhesion in cervical cancer. Biomed
Res Int. 2014:5814032014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mirisola V, Zuccarino A, Bachmeier BE,
Sormani MP, Falter J, Nerlich A and Pfeffer U: CXCL12/SDF1
expression by breast cancers is an independent prognostic marker of
disease-free and overall survival. Eur J Cancer. 45:2579–2587.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Roy I, Zimmerman NP, Mackinnon AC, Tsai S,
Evans DB and Dwinell MB: CXCL12 chemokine expression suppresses
human pancreatic cancer growth and metastasis. PLoS One.
9:e904002014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wendt MK, Johanesen PA, Kang-Decker N,
Binion DG, Shah V and Dwinell MB: Silencing of epithelial CXCL12
expression by DNA hypermethylation promotes colonic carcinoma
metastasis. Oncogene. 25:4986–4997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Williams SA, Harata-Lee Y, Comerford I,
Anderson RL, Smyth MJ and McColl SR: Multiple functions of CXCL12
in a syngeneic model of breast cancer. Mol Cancer. 9:2502010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gong X, Yang T, Liu W, Liao K and He W:
Expression and clinical significance of chemokine receptor CXCR4 in
non-small cell lung cancer. J Trop Med. 16:829–831. 2016.(In
Chinese).
|
|
34
|
Popper HH: Progression and metastasis of
lung cancer. Cancer Metastasis Rev. 35:75–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Righi E, Kashiwagi S, Yuan J, Santosuosso
M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing
D, et al: CXCL12/CXCR4 blockade induces multimodal antitumor
effects that prolong survival in an immunocompetent mouse model of
ovarian cancer. Cancer Res. 71:5522–5534. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Choi YH, Burdick MD, Strieter BA, Mehrad B
and Strieter RM: CXCR4, but not CXCR7, discriminates metastatic
behavior in non-small cell lung cancer cells. Mol Cancer Res.
12:38–47. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rivas-Fuentes S, Salgado-Aguayo A, Belloso
Pertuz S, Rosete Gorocica P, Alvarado-Vasquez N and Aquino-Jarquin
G: Role of chemokines in non-small cell lung cancer: Angiogenesis
and inflammation. J Cancer. 6:938–952. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Iakovlev VV, Gabril M, Dubinski W,
Scorilas A, Youssef YM, Faragalla H, Kovacs K, Rotondo F, Metias S,
Arsanious A, et al: Microvascular density as an independent
predictor of clinical outcome in renal cell carcinoma: An automated
image analysis study. Lab Invest. 92:46–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Weidner N, Carroll PR, Flax J, Blumenfeld
W and Folkman J: Tumor angiogenesis correlates with metastasis in
invasive prostate carcinoma. Am J Pathol. 143:401–409.
1993.PubMed/NCBI
|
